Compugen 미래 성장
Future 기준 확인 0/6
Compugen 의 수익은 연간 59.8% 감소할 것으로 예상되는 반면, 연간 수익은 2.3% 로 증가할 것으로 예상됩니다. 2.3% 연간. EPS는 연간 59.1% 만큼 쇠퇴할 것으로 예상됩니다.
주요 정보
-59.8%
수익 성장률
-59.1%
EPS 성장률
| Biotechs 수익 성장 | 28.3% |
| 매출 성장률 | 2.3% |
| 향후 자기자본 수익률 | n/a |
| 애널리스트 커버리지 | Low |
| 마지막 업데이트 | 13 Nov 2024 |
최근 미래 성장 업데이트
Recent updates
Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues
Aug 22
Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report
May 22Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge
May 01Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?
Apr 05Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Mar 08Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans
Feb 17Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?
Oct 10Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?
Jun 22Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation
Mar 04Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Sep 21Compugen appoints Alberto Sessa as CFO
Sep 12Compugen gets Japanese patent for COM701, anti-PVRIG antibodies
Aug 24Compugen Q2 2022 Earnings Preview
Aug 03Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Jun 23Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Mar 02Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation
Nov 04Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation
Aug 27Companies Like Compugen (NASDAQ:CGEN) Can Afford To Invest In Growth
Jun 28Compugen gains on takeover speculation after iTeos Therapeutics deal
Jun 14Compugen reports updated COM701 data from Phase 1 study at ASCO21
Jun 08Compugen's COM902 demonstrates potential benefit in cancer
Apr 27Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation
Mar 15Are Institutions Heavily Invested In Compugen Ltd.'s (NASDAQ:CGEN) Shares?
Feb 08
A Look At The Fair Value Of Compugen Ltd. (NASDAQ:CGEN)
Jan 04Compugen earns $2M milestone under antibody development deal with AstraZeneca
Dec 23Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation
Nov 30Compugen Ltd. 2020 Q3 - Results - Earnings Call Presentation
Nov 08Compugen: Speculative Play For Immuno-Oncology Exposure
Nov 07수익 및 매출 성장 예측
| 날짜 | 수익 | 수익 | 잉여 현금 흐름 | 작전 현금 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2026 | 47 | -6 | 7 | N/A | 2 |
| 12/31/2025 | 40 | -6 | -10 | N/A | 2 |
| 12/31/2024 | 51 | 3 | 97 | N/A | 2 |
| 9/30/2024 | 60 | 2 | N/A | N/A | N/A |
| 6/30/2024 | 43 | -10 | 22 | 22 | N/A |
| 3/31/2024 | 36 | -17 | N/A | N/A | N/A |
| 12/31/2023 | 33 | -19 | -36 | -36 | N/A |
| 9/30/2023 | 8 | -32 | N/A | N/A | N/A |
| 6/30/2023 | 8 | -33 | -32 | -32 | N/A |
| 3/31/2023 | 8 | -33 | N/A | N/A | N/A |
| 12/31/2022 | 8 | -34 | -35 | -34 | N/A |
| 9/30/2022 | N/A | -39 | N/A | N/A | N/A |
| 6/30/2022 | 6 | -34 | -30 | -30 | N/A |
| 3/31/2022 | 6 | -34 | N/A | N/A | N/A |
| 12/31/2021 | 6 | -34 | -23 | -23 | N/A |
| 9/30/2021 | 8 | -34 | N/A | N/A | N/A |
| 6/30/2021 | 2 | -36 | -31 | -30 | N/A |
| 3/31/2021 | 2 | -32 | N/A | N/A | N/A |
| 12/31/2020 | 2 | -30 | -28 | -28 | N/A |
| 9/30/2020 | N/A | -28 | N/A | N/A | N/A |
| 6/30/2020 | N/A | -26 | -23 | -23 | N/A |
| 3/31/2020 | N/A | -26 | N/A | N/A | N/A |
| 12/31/2019 | N/A | -27 | -28 | -28 | N/A |
| 9/30/2019 | N/A | -30 | N/A | N/A | N/A |
| 6/30/2019 | 8 | -27 | -22 | -22 | N/A |
| 3/31/2019 | 8 | -31 | N/A | N/A | N/A |
| 12/31/2018 | 18 | -23 | -13 | -13 | N/A |
| 9/30/2018 | 18 | -23 | N/A | N/A | N/A |
| 6/30/2018 | 10 | -29 | N/A | -23 | N/A |
| 3/31/2018 | 10 | -28 | N/A | N/A | N/A |
| 12/31/2017 | N/A | -37 | N/A | -31 | N/A |
| 9/30/2017 | 0 | -36 | N/A | N/A | N/A |
| 6/30/2017 | 0 | -34 | N/A | -27 | N/A |
| 3/31/2017 | 1 | -32 | N/A | N/A | N/A |
| 12/31/2016 | 1 | -32 | N/A | -20 | N/A |
| 9/30/2016 | 9 | -23 | N/A | N/A | N/A |
| 6/30/2016 | 9 | -22 | N/A | -20 | N/A |
| 3/31/2016 | 9 | -23 | N/A | N/A | N/A |
| 12/31/2015 | 9 | -20 | N/A | -26 | N/A |
| 9/30/2015 | 8 | -21 | N/A | N/A | N/A |
| 6/30/2015 | 9 | -20 | N/A | -17 | N/A |
| 3/31/2015 | 11 | -15 | N/A | N/A | N/A |
| 12/31/2014 | 12 | -11 | N/A | -11 | N/A |
| 9/30/2014 | 8 | -13 | N/A | N/A | N/A |
| 6/30/2014 | 7 | -12 | N/A | -7 | N/A |
| 3/31/2014 | 6 | -13 | N/A | N/A | N/A |
| 12/31/2013 | 4 | -14 | N/A | -6 | N/A |
애널리스트 미래 성장 예측
수입 대 저축률: CGEN 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -59.8% ).
수익 vs 시장: CGEN 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -59.8% ).
고성장 수익: CGEN 의 수익은 향후 3년간 감소할 것으로 예상됩니다.
수익 대 시장: CGEN 의 수익(연간 2.3% ) US 시장( 8.9% 보다 느리게 성장할 것으로 예상됩니다. 8.9% 연간).
고성장 수익: CGEN 의 수익(연간 2.3% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.
주당 순이익 성장 예측
미래 자기자본 수익률
미래 ROE: CGEN 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.